Today (Friday 15 August 2014) the National Institute for Health and Care Excellence (NICE) confirmed its refusal to let men with advanced prostate cancer have abiraterone, which could extend life and delay their need for chemotherapy with its devastating side effects. Prostate Cancer UK is urging NICE and the manufacturer to work together and do whatever is necessary to make the drug available without further delay.

Read more